Allergy

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

Retrieved on: 
Sunday, November 5, 2023
Prior, News, Pomerantz, LLP, Risk, Allergy, Hypersensitivity, Private investigator

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether SCYNEXIS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023
CSU, DLQI, Prurigo, Science, Survival, WCI, KIT, Research, Dermatology Life Quality Index, PN, Contingency, Congress, G&A, Work, B cell, PD-1, Cell, R, Quality of life, European Academy of Management, SD, Prurigo nodularis, Myelocyte, Disease, UCT, Eosinophilic esophagitis, Allergy, Georgia World Congress Center, ILT4, Therapy, Patient, Rockefeller University, SCF, Hypersensitivity, D, Pharmaceutical industry, Vaccine, Rare-earth element, Cryptocurrency, Dermatology

HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment complete; topline data by YE 2023 -
    HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In July 2023, Celldex announced that enrollment to the CSU study (n=208) had been completed and that topline data is anticipated by the end of 2023.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2023 were $235.3 million compared to $252.7 million as of June 30, 2023.

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
FDA, Research and development, Trial of the century, IND, American College, Association of International Accountants, Food, 2023 International Conference on Climate Resilient Pakistan, ACAAI, Conference, Asthma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hereditary angioedema, R, Bank statement, HAE, American College of Allergy, Asthma and Immunology, ACIS, Abstract, Record, Safety, Attack, Patient, International Accounting Standards Board, Communication, Book, Administration, CIIC, Pharmaceutical industry, Cryptocurrency, Allergy

Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.

Key Points: 
  • Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.
  • R&D expenses were €18.5 million for the quarter ended September 30, 2023, compared to €14.1 million for the quarter ended September 30, 2022.
  • G&A expenses were €7.7 million for the quarter ended September 30, 2023, compared to €8.3 million for the quarter ended September 30, 2022.
  • Details are as follows:
    Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: SPRY)

Retrieved on: 
Thursday, November 2, 2023
Allergy, CRL, FDA, Adrenaline, Fraud, News, Symantec Endpoint Protection, Food, ARS, Food and Drug Administration, Pharmaceutical industry

The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.

Key Points: 
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain ARS investors.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

DBV Technologies to Present New Data at ACAAI 2023

Retrieved on: 
Thursday, November 2, 2023
Aurora, Panel discussion, FDA, American College, DBV, Food, Biologics license application, ACAAI, Safety, European Medicines Agency, MBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, PST, Immune system, Risk, Asthma, DRS, DBV Technologies, Allergy, Children's Hospital Colorado, Patient, BLA, Pharmaceutical industry, Vaccine, Euronext

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
  • The presentation will be available on DBV’s website, www.dbv-technologies.com , following the conclusion of the meeting for those who are unable to attend.
  • In addition, DBV is a 2023 ACAAI Benefactor Level Corporate Council Member.
  • The Company will also host a booth in the ACAAI Exhibit Hall from Saturday, November 11 – Monday, November 13th.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc. (SPRY)

Retrieved on: 
Wednesday, November 1, 2023
FDA, Food, Telephone, Adrenaline, Symantec Endpoint Protection, News, ARS, CRL, Levi, Allergy, Food and Drug Administration, Pharmaceutical industry

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Following this news, ARS’ stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws

Retrieved on: 
Tuesday, October 31, 2023
Allergy, CRL, Vincent Wong, FDA, Law, Adrenaline, News, Symantec Endpoint Protection, Law officers of the Crown, Food, ARS, Food and Drug Administration, Pharmaceutical industry

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:

Key Points: 
  • NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:
    The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and directors regarding potential securities fraud.
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
Monday, October 30, 2023
Neoplasm, PDUFA, Food, Dysgeusia, Rash, Vitamin, Vonoprazan, Abdomen, Clarithromycin, Liver, Chills, Pain, Hypersensitivity, Infection, Allergy, Azithromycin, Rilpivirine, Diarrhea, Liver disease, Tablet, Medicine, Genetically modified bacteria, Drug, Safety, Patient, Chronic pain, DUAL, Catalent, History, Weight loss, Colchicine, GERD, Helicobacter pylori, Fever, Calcium channel, Common, PAS, Jaundice, CGA, Abdominal pain, FDA, Infectious mononucleosis, Headache, Aes, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Candidiasis, Erythromycin, Urine, Hypertension, Breast milk, Blood, AE, Pharmaceutical industry, Vaccine, Soft drink, Teahouse, Antibiotics, Medicinal plants, Dietary supplement, Birth control, Amoxicillin, Emtricitabine/rilpivirine/tenofovir

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: SPRY)

Retrieved on: 
Monday, October 30, 2023
Allergy, CRL, FDA, Adrenaline, Fraud, News, Symantec Endpoint Protection, Food, ARS, Food and Drug Administration, Pharmaceutical industry

The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.

Key Points: 
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain ARS investors.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

Retrieved on: 
Friday, October 27, 2023
Prior, News, Pomerantz, LLP, Risk, Allergy, Hypersensitivity, Private investigator

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX).

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether SCYNEXIS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.